Claims for Patent: 11,918,565

Summary for Patent: 11,918,565

Title:	Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
Abstract:	Provided herein are methods of administering to a peroneal and a tibial nerve of a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of a patient; (b) inserting the injection needle into the patient at the entry point; (c) administering to a sciatic nerve of the patient via the injection needle saline and a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome.
Inventor(s):	Roy Winston, Mary DiGiorgi
Assignee:	Pacira Pharmaceuticals Inc
Application Number:	US18/104,970
Patent Claims:	1. A method of administering regional analgesia comprising a sciatic nerve block in the popliteal fossa of a patient, the method comprising: a) selecting an entry point of an injection needle in a leg of the patient; b) inserting the injection needle into the patient at the entry point; c) administering to a sciatic nerve sheath of the patient via the injection needle 133 mg of a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome, thereby administering the regional analgesia comprising the sciatic nerve block in the popliteal fossa of the patient. 2. The method of claim 1, wherein the injection needle is connected to a peripheral nerve stimulator (PNS). 3. The method of claim 2, wherein the PNS is used to identify the region where the sciatic nerve splits into the peroneal and tibial nerves. 4. The method of claim 1, wherein the injection needle is a 100 mm, 21-gauge needle. 5. The method of claim 1, wherein the insertion of the injection needle into the leg of the patient comprises piercing the perineural sheath. 6. The method of claim 1, wherein the entry point of the injection needle is in the lateral thigh. 7. The method of claim 1, wherein the method comprises administering about 30 mL of the pharmaceutical composition. 8. The method of claim 1, wherein the multivesicular liposomes comprise: bupivacaine or a salt thereof; phosphoric acid; a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and, optionally, a cholesterol and/or a plant sterol, wherein said multivesicular liposomes are made by a process comprising: a) preparing a first aqueous component comprising phosphoric acid; b) preparing a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and at least one neutral lipid lacking a hydrophilic head group; c) mixing said first aqueous component and said lipid component to form a water-in-oil emulsion, wherein at least one component comprises bupivacaine or a salt thereof; d) mixing said water-in-oil emulsion with a second aqueous component to form solvent spherules; and e) removing the organic solvent from the solvent spherules to form multivesicular liposomes encapsulating bupivacaine phosphate. 9. The method of claim 1, further comprising administering to the patient a Mayo Field Block encircling the entire metatarsal bone. 10. A method of administering to a peroneal and a tibial nerve of a human patient a pharmaceutical composition for post-operative analgesia, the method comprising: a) selecting an entry point of an injection needle in a leg in a patient; b) advancing a needle tip of the injection needle within a region where the sciatic nerve splits into the peroneal and tibial nerves of the patient along a trajectory that extends between the entry point and where the sciatic nerve splits into the peroneal and tibial nerves; c) administering to said region through the injection needle 133 mg of a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome, thereby administering to the peroneal and the tibial nerve of the human patient the pharmaceutical composition for post-operative analgesia. 11. The method of claim 10, wherein the injection needle is connected to a peripheral nerve stimulator (PNS). 12. The method of claim 11, wherein the PNS is used to identify the region where the sciatic nerve splits into the peroneal and tibial nerves. 13. The method of claim 11, wherein the injection needle is a 100 mm, 21-gauge needle. 14. The method of claim 11, wherein the entry point of the injection needle is in the lateral thigh. 15. The method of claim 10, wherein the method comprises administering about mL of the pharmaceutical composition. 16. The method of claim 10, wherein the multivesicular liposomes comprise: bupivacaine or a salt thereof; phosphoric acid; a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and, optionally, a cholesterol and/or a plant sterol, wherein said multivesicular liposomes are made by a process comprising: a) preparing a first aqueous component comprising phosphoric acid; b) preparing a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and at least one neutral lipid lacking a hydrophilic head group; c) mixing said first aqueous component and said lipid component to form a water-in-oil emulsion, wherein at least one component comprises bupivacaine or a salt thereof; d) mixing said water-in-oil emulsion with a second aqueous component to form solvent spherules; and e) removing the organic solvent from the solvent spherules to form multivesicular liposomes encapsulating bupivacaine phosphate. 17. A method of administering postsurgical regional analgesia to a foot in a patient, the method comprising: a) selecting an entry point of an injection needle in a leg of the patient; b) inserting the injection needle into the leg of the patient at the entry point; c) administering to the patient 133 mg of a pharmaceutical composition within a sciatic nerve sheath; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome, thereby administering postsurgical regional analgesia to a foot in the patient. 18. The method of claim 17, wherein a peripheral nerve stimulator (PNS) is used to identify the region where the sciatic nerve splits into the peroneal and tibial nerves. 19. The method of claim 17, wherein the injection needle is a 100 mm, 21-gauge needle. 20. The method of claim 17, wherein inserting the injection needle into the leg of the patient comprises advancing a needle tip of the injection needle within a region where the sciatic nerve splits into the peroneal and tibial nerves of the patient along a trajectory that extends between the entry point and the region where the sciatic nerve splits into the peroneal and tibial nerves. 21. The method of claim 17, wherein the insertion of the injection needle into the leg of the patient comprises piercing the perineural sheath. 22. The method of claim 17, wherein the method comprises administering about mL of the pharmaceutical composition. 23. The method of claim 17, wherein the multivesicular liposomes comprise: bupivacaine or a salt thereof; phosphoric acid; a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and, optionally, a cholesterol and/or a plant sterol, wherein said multivesicular liposomes are made by a process comprising: a) preparing a first aqueous component comprising phosphoric acid; b) preparing a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and at least one neutral lipid lacking a hydrophilic head group; c) mixing said first aqueous component and said lipid component to form a water-in-oil emulsion, wherein at least one component comprises bupivacaine or a salt thereof; d) mixing said water-in-oil emulsion with a second aqueous component to form solvent spherules; and e) removing the organic solvent from the solvent spherules to form multivesicular liposomes encapsulating bupivacaine phosphate. 24. The method of claim 17, further comprising administering to the patient a Mayo Field Block encircling the entire metatarsal bone. 25. A method of administering a sciatic nerve block in a popliteal fossa to reduce post-operative foot pain in a patient, the method comprising: a) selecting an entry point of an injection needle in a leg of the patient; b) advancing a needle tip of the injection needle within a region where the sciatic nerve splits into the peroneal and tibial nerves of the patient along a trajectory that extends between the entry point and the region where the sciatic nerve splits into the peroneal and tibial nerves; c) piercing with the needle tip of the injection needle the sciatic nerve sheath in said region; d) administering through the injection needle 133 mg of a multivesicular liposome pharmaceutical composition; wherein the multivesicular liposome pharmaceutical composition comprises: bupivacaine or a salt thereof; phosphoric acid; a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and, optionally, a cholesterol and/or a plant sterol, thereby administering a sciatic nerve block in the popliteal fossa to reduce post-operative foot pain in the patient. 26. The method of claim 25, wherein a peripheral nerve stimulator (PNS) is used to identify the region where the sciatic nerve splits into the peroneal and tibial nerves. 27. The method of claim 25, wherein the method comprises administering about mL of the pharmaceutical composition. 28. The method of claim 25, further comprising administering to the patient a Mayo Field Block encircling the entire metatarsal bone. 29. The method of claim 25, wherein the sciatic nerve is located by way of ultrasound guidance. 30. The method of claim 1, wherein inserting the injection needle into the leg of the patient comprises advancing a needle tip of the injection needle within a region where the sciatic nerve splits into the peroneal and tibial nerves of the patient along a trajectory that extends between the entry point and the region where the sciatic nerve splits into the peroneal and tibial nerves.